News

PredictImmune announces new ‘framework agreement’ with Cambridge Enterprise to allow future expansion of original IP license to expand its...

PredictImmune and CEO Paul Kinnon announced as finalists in the Cambridge Independent Science and Technology Awards 2019Cambridge, UK, September...

PredictImmune appoints Tim Rea of BGF as non-executive directorExperienced entrepreneur and investor appointed with immediate effect Cambridge, UK,...

PredictImmune closes Series B funding round, raising £10M to further accelerate global commercial expansion and support expanding product...

Gut publication extends follow-up for PredictImmune’s blood-based prognostic biomarker in IBD.Cambridge, UK, 2nd May 2019:  Longer-term follow-up...

PredictImmune’s first prognostic test for IBD, PredictSURE® IBD, launches in the UK and IrelandpeThe world’s first validated prognostic test for...

PredictImmune’s first prognostic test, PredictSURE® IBD, set for UK and European launch having been awarded CE markAchievement marks significant...

Crohn’s Disease PROFILE Trial Protocol Published Cambridge, UK, 06 December 2018: The PROFILE trial is the first biomarker-stratified study in...

PredictImmune joins the British In vitro Device Association (BIVDA)Cambridge, UK, 13th November 2018: With the launch of its first product imminent,...